We first showed that candesartan and azilsartan could alleviate insulin resistance in PA-treated HepG2 cells by fully restoring the impaired insulin-stimulated phosphorylation of AKT and its downstream substrates GSK3β, AS160, FOXO1, and FOXO3. The gene discussed is FOXO3; the disease is Insulin resistance.